Search results
Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
- 475.93Add to watchlist+3.42 (+0.72%)As of Fri. Jun 28, 2024 1:39 PM EDT · Nasdaq Real Time Price (USD) · Market open
- Open473.21High477.31Low470.67
- Mkt Cap122.82BP/E (TTM)30.90Div & YieldN/A & N/A
- Prev. Close472.5152 Wk. Low335.8252 Wk. High486.43
What analysts are sayingTop storiesThe Cream Of The Crop: 5 Biotechs That Outrank Most StocksInvestor's Business Daily · 2 hours ago- VRTX +0.72%
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on ItYahoo Finance · 2 days ago- VRTX +0.72%
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to NoteYahoo Finance · 4 days agoRelated stocks
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.
Dec 8, 2023 · Vertex leads global development, manufacturing and commercialization of CASGEVY with support from CRISPR Therapeutics. In conjunction with the FDA approval of CASGEVY, Vertex will make a $200 million milestone payment to CRISPR, which will be capitalized and amortized to cost of sales.
4 days ago · The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
Jul 11, 2022 · Vertex’s VX-880, an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy for T1D, has already achieved proof-of-concept with highly promising safety and efficacy results from an ongoing Phase 1/2 study which continues to enroll and dose patients.